Ana Clara P. Azevedo‐Pouly

Role not yet determined Is this you? Add your title

UAMS primary NCTR

Also affiliated: United States Food and Drug Administration (2019–2022); University of Utah (2017); University of Florida (2022); Arkansas Children's Research Institute (2021–2026); The Ohio State University (2011–2017); The University of Texas Southwestern Medical Center (2016–2023)

13 h-index 35 pubs 790 cited

Research Areas

Biomedical Subjects

Links

ORCID Lab Website

OverviewAI-generated summary

Ana Clara P. Azevedo‐Pouly's research focuses on understanding the molecular mechanisms regulating cell identity and homeostasis, particularly in the context of pancreatic development and cancer. Her work has investigated the roles of key transcription factors, such as PTF1A and MIST1, in maintaining the pancreatic acinar phenotype in adult mice. Azevedo‐Pouly has also explored the involvement of microRNAs in cancer, including their potential as therapeutic agents and their function in regulating tumor suppressor genes in breast cancer. Her research utilizes various model systems, including mice and cell lines, and employs techniques for RNA isolation from challenging tissues. She has a record of 34 publications, with an h-index of 13 and 786 citations. Azevedo‐Pouly collaborates with researchers at the University of Arkansas for Medical Sciences, including Randall R Rainwater, Brian Koss, Lauren Appell, and Melanie Barker.

Metrics

h-index: 13
Publications: 35
Citations: 790

Selected Publications

DNA-PKcs Controls the Cytotoxic T-Cell Response to Cancer and Transplant Allograft Through Regulating LAT-Dependent Signaling (2025)

SSRN Electronic Journal DOI OpenAlex
DNA-PKcs governs LAT-dependent signaling in CD4 + and CD8 + T cells (2025)

bioRxiv (Cold Spring Harbor Laboratory) DOI OpenAlex
The use of DNAPK inhibitors increases the efficacy of Lentiviral vectors and decreases off-target effects. (2024)

The Journal of Immunology DOI OpenAlex
Discovery of the DNA-PKcs inhibitor DA-143 which exhibits enhanced solubility relative to NU7441 (2024)

Scientific Reports 3 citations DOI OpenAlex
Chemical inhibition of DNA‐PKcs impairs the activation and cytotoxicity of CD4 + helper and CD8 + effector T cells (2023)

Immunology and Cell Biology 7 citations DOI OpenAlex
DNA-PKcs is required for the activation and cytotoxicity of CD8+ effector T cells (2022)

The Journal of Immunology DOI OpenAlex
Potential role of the apelin‐APJ pathway in sex‐related differential cardiotoxicity induced by doxorubicin in mice (2022)

Journal of Applied Toxicology 8 citations DOI OpenAlex
Pharmacological inhibition and reversal of pancreatic acinar ductal metaplasia (2022)

Cell Death Discovery 22 citations DOI OpenAlex
Inhibition of DNA-PKcs impairs the activation and cytotoxicity of CD4 + helper and CD8 + effector T cells (2022)

bioRxiv (Cold Spring Harbor Laboratory) DOI OpenAlex
DNA-PKcs kinase activity stabilizes the transcription factor Egr1 in activated immune cells (2021)

Journal of Biological Chemistry 22 citations DOI OpenAlex
DNA-PKcs kinase activity stabilizes the transcription factor Egr1 in activated immune cells (2021)

bioRxiv (Cold Spring Harbor Laboratory) 1 citation DOI OpenAlex
Concerted cell and in vivo screen for pancreatic ductal adenocarcinoma (PDA) chemotherapeutics (2020)

Scientific Reports 3 citations DOI OpenAlex
Knockout of Acinar Enriched microRNAs in Mice Promote Duct Formation But Not Pancreatic Cancer (2019)

Scientific Reports 19 citations DOI OpenAlex